Autoimmune storm following alemtuzumab

Area of Science:

• Neurology
• Immunology
• Hematology

Background:

• Alemtuzumab is a monoclonal antibody used to treat relapsing-remitting multiple sclerosis (MS).
• Alemtuzumab is known to cause secondary autoimmune conditions.
• The development of multiple, concurrent autoimmune diseases post-alemtuzumab is rare.

Observation:

• A patient with relapsing-remitting MS was treated with alemtuzumab.
• The patient subsequently developed refractory immune thrombocytopaenia.
• The patient also experienced vasculitis, myelofibrosis, and Guillain-Barré syndrome.

Findings:

• This case demonstrates a complex autoimmune presentation following alemtuzumab therapy.
• The patient exhibited concurrent immune thrombocytopaenia, vasculitis, myelofibrosis, and Guillain-Barré syndrome.
• These adverse events were refractory to treatment.

Implications:

• Clinicians should maintain a high index of suspicion for unusual autoimmune sequelae after alemtuzumab treatment.
• Simultaneous occurrence of multiple autoimmune diseases warrants careful investigation and management.
• Awareness of these potential adverse events is crucial for patient safety in MS management.